Accelerating drug development through collaboration

The Hepatitis C drug development advisory group

C. Hutchison, A. Kwong, Stuart Campbell Ray, K. Struble, T. Swan, V. Miller

Research output: Contribution to journalArticle

Abstract

Over the past decade, landmark collaboration between regulatory agencies, pharmaceutical companies, academia, and patient community representatives has enabled the development and approval of new hepatitis C virus (HCV) treatment regimens with unprecedented speed. By providing a neutral platform for cross-sector engagement, the Forum for Collaborative HIV Research's 1 HCV Drug Development Advisory Group played a critical role in fostering this collaboration and expediting drug development. The applicability of this model to other therapeutic areas should be explored.

Original languageEnglish (US)
Pages (from-to)162-165
Number of pages4
JournalClinical Pharmacology and Therapeutics
Volume96
Issue number2
DOIs
StatePublished - 2014

Fingerprint

Hepatitis C
Hepacivirus
Pharmaceutical Preparations
Patient Advocacy
Foster Home Care
HIV-1
Therapeutics
Research

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Accelerating drug development through collaboration : The Hepatitis C drug development advisory group. / Hutchison, C.; Kwong, A.; Ray, Stuart Campbell; Struble, K.; Swan, T.; Miller, V.

In: Clinical Pharmacology and Therapeutics, Vol. 96, No. 2, 2014, p. 162-165.

Research output: Contribution to journalArticle

Hutchison, C. ; Kwong, A. ; Ray, Stuart Campbell ; Struble, K. ; Swan, T. ; Miller, V. / Accelerating drug development through collaboration : The Hepatitis C drug development advisory group. In: Clinical Pharmacology and Therapeutics. 2014 ; Vol. 96, No. 2. pp. 162-165.
@article{8170cd91cd314213b44610cf86890c9a,
title = "Accelerating drug development through collaboration: The Hepatitis C drug development advisory group",
abstract = "Over the past decade, landmark collaboration between regulatory agencies, pharmaceutical companies, academia, and patient community representatives has enabled the development and approval of new hepatitis C virus (HCV) treatment regimens with unprecedented speed. By providing a neutral platform for cross-sector engagement, the Forum for Collaborative HIV Research's 1 HCV Drug Development Advisory Group played a critical role in fostering this collaboration and expediting drug development. The applicability of this model to other therapeutic areas should be explored.",
author = "C. Hutchison and A. Kwong and Ray, {Stuart Campbell} and K. Struble and T. Swan and V. Miller",
year = "2014",
doi = "10.1038/clpt.2014.113",
language = "English (US)",
volume = "96",
pages = "162--165",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - Accelerating drug development through collaboration

T2 - The Hepatitis C drug development advisory group

AU - Hutchison, C.

AU - Kwong, A.

AU - Ray, Stuart Campbell

AU - Struble, K.

AU - Swan, T.

AU - Miller, V.

PY - 2014

Y1 - 2014

N2 - Over the past decade, landmark collaboration between regulatory agencies, pharmaceutical companies, academia, and patient community representatives has enabled the development and approval of new hepatitis C virus (HCV) treatment regimens with unprecedented speed. By providing a neutral platform for cross-sector engagement, the Forum for Collaborative HIV Research's 1 HCV Drug Development Advisory Group played a critical role in fostering this collaboration and expediting drug development. The applicability of this model to other therapeutic areas should be explored.

AB - Over the past decade, landmark collaboration between regulatory agencies, pharmaceutical companies, academia, and patient community representatives has enabled the development and approval of new hepatitis C virus (HCV) treatment regimens with unprecedented speed. By providing a neutral platform for cross-sector engagement, the Forum for Collaborative HIV Research's 1 HCV Drug Development Advisory Group played a critical role in fostering this collaboration and expediting drug development. The applicability of this model to other therapeutic areas should be explored.

UR - http://www.scopus.com/inward/record.url?scp=84904857264&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84904857264&partnerID=8YFLogxK

U2 - 10.1038/clpt.2014.113

DO - 10.1038/clpt.2014.113

M3 - Article

VL - 96

SP - 162

EP - 165

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 2

ER -